While caution must be exercised due to the single case nature of the data, the fact that LY remained partially efficacious in an animal at the late stage of disease development opens the possibility that FGF21 based therapy may have therapeutic utility in patients with well advanced type 2 diabetes. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.